These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
4. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases. Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M Clin Transpl; 2009; ():361-8. PubMed ID: 20524299 [No Abstract] [Full Text] [Related]
6. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS Clin Transpl; 2009; ():407-14. PubMed ID: 20524306 [No Abstract] [Full Text] [Related]
8. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA Clin Transpl; 2010; ():391-6. PubMed ID: 21696056 [TBL] [Abstract][Full Text] [Related]
11. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection. Al Meshari K Clin Transpl; 2009; ():385-6. PubMed ID: 20524302 [No Abstract] [Full Text] [Related]
12. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG Clin Transpl; 2009; ():465-9. PubMed ID: 20524316 [TBL] [Abstract][Full Text] [Related]
14. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
15. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports. Wong W; Lee RA; Saidman SL; Smith RN; Zorn E Clin Transpl; 2009; ():401-5. PubMed ID: 20524305 [TBL] [Abstract][Full Text] [Related]
17. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES Clin Transpl; 2009; ():475-8. PubMed ID: 20524318 [TBL] [Abstract][Full Text] [Related]
19. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Nguyen S; Gallay B; Butani L Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]